This study compared the immunogenicity , reactogenicity and safety of the MF59-adjuvanted trivalent subunit vaccine ( aTIV ) with two non-adjuvanted trivalent vaccines , TIV-1 , the non-adjuvanted version of aTIV , and TIV-2 , a split virion vaccine .